Clinical trial

Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

NCT04909255

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record mirabegron Normalized identity: mirabegronView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention oxybutynin, tolterodine, solifenacin Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-03-23

PhasePHASE4

Conditions

Sjogren's Syndromeunresolved

Overactive Bladder Syndromeunresolved

Interventions

mirabegronDRUG · verified · RxNorm: mirabegron

oxybutynin, tolterodine, solifenacinDRUG

Sponsors & collaborators

China Medical University Hospitallead sponsor

Mapped research locations

TaichungTaiwan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04909255 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.